Company intelligence / Profile preview

Tear Film Innovations

Carlsbad, California, United Statesnovartis.com ↗

Ownership: Private
Employees: ~3
Development stage: Other

Overview

Tear Film Innovations developed the iLux® device for the treatment of meibomian gland dysfunction—a leading cause of evaporative dry eye. The iLux® system uses light-based heat and manual compression to unblock meibomian glands during an in-office procedure. The product received FDA clearance in late 2017 and was launched commercially in mid–2018. It was well-received by ophthalmologists prior to the company’s acquisition by Alcon at the end of 2018.

Therapeutic areas: Ophthalmology
Modalities: Device
Industry: Therapeutic Medical Devices

Partnerships

None publicly disclosed; post-acquisition all partnerships are under Alcon.

Beyond the preview

Go deeper on Tear Film Innovations.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tear Film Innovations.

Explore the full profile